Headlands Technologies LLC Sells 69,094 Shares of Pfizer Inc. (NYSE:PFE)

Headlands Technologies LLC cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 89.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,793 shares of the biopharmaceutical company's stock after selling 69,094 shares during the quarter. Headlands Technologies LLC's holdings in Pfizer were worth $207,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in Pfizer in the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at about $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE traded down $0.38 during trading on Tuesday, hitting $22.25. The stock had a trading volume of 27,770,938 shares, compared to its average volume of 46,389,902. The firm has a market cap of $126.18 billion, a PE ratio of 15.78, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $21.75 and a 12 month high of $31.54. The company has a 50 day simple moving average of $25.79 and a 200-day simple moving average of $26.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.10 earnings per share. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of several analyst reports. Bank of America restated a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial decreased their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.